Zika virus infects and crosses the placentas of pregnant mice and causes severe damage or death in fetal mice, report scientists funded by the National Institutes of Health. Investigators from the Washington University School of Medicine in St. Louis have developed two mouse models of Zika infection in pregnancy that will enable rapid testing of experimental Zika drugs to prevent congenital abnormalities, and may aid in better understanding how the virus affects pregnant women.
The team, led by Michael S. Diamond, M.D., Ph.D., created two ways to model Zika infection in pregnancy. One system used female mice genetically engineered to lack the ability to mount a specific immune response, which made them susceptible to Zika virus infection. When these pregnant mice were exposed to Zika, the virus killed most fetuses within a week. The fetal mice that survived showed significant abnormalities, such as severely stunted growth. The researchers saw levels of viral genetic material in the mouse placentas that were 1,000 times greater than in the blood of pregnant mice, suggesting that Zika virus replicated preferentially within the placenta.
In the second model system, genetically normal pregnant mice were first given an antibody that blocked their immune response to Zika virus and then were infected with Zika virus one or two days later. This model did not lead to death of fetal mice, but their growth was impaired. The investigators determined that viral genetic material persisted in fetal heads and bodies through at least day 16 of embryonic development, a critical period in mouse brain development.
Mouse models of Zika infection in pregnancy could be used to rapidly assess the effectiveness of candidate drugs or other interventions, the investigators note. For example, recent experiments by NIH-funded researchers at the University of Pittsburgh showed that the immune system protein interferon-lambda prevents Zika virus from infecting a key type of human placental cell. Dr. Diamond and his colleague Helen Lazear, Ph.D., of the University of North Carolina at Chapel Hill, are planning studies to test whether interferon-lambda can prevent the transmission of Zika virus from pregnant mice to their offspring.
ARTICLE: JJ Miner et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell DOI: 10.1016/j.cell.2016.05.008 (2016).
WHO: Anthony S. Fauci, M.D., director, National Institute of Allergy and Infectious Diseases (NIAID), and Cristina Cassetti, Ph.D., program director in NIAID's Division of Microbiology and Infectious Diseases, are available to comment on this research.
CONTACT: To schedule interviews with NIAID officials, please contact Anne A. Oplinger, (301) 402-1663, email@example.com.
To arrange interviews with the paper's corresponding co-authors Dr. Diamond or Indira Mysorekar, Ph.D., please contact Judy Martin Finch, (314) 826-0105 or firstname.lastname@example.org.
This research was supported by these grants from the NIH: NIAID grants AI073755, AI04972, and AI00763; National Child Health and Human Development grants HD052664 and HD087011; National Institute of Neurological Disorders and Stroke grant NS052632; and National Human Genome Research Institute grant HG006687.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health®